Spots Global Cancer Trial Database for Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy
Official Title: An Open-label, Multicenter, Phase II Study to Evaluate the Ability of Glivec® (Imatinib, Formerly Known as STI571) to Produce a Biochemical Response in Patients With Rising PSA Following Radical Prostatectomy
Study ID: NCT01316458
Interventions
Study Description
Brief Summary: To investigate the ability of 600 mg of Glivec®, given once daily by mouth to patients with rising PSA following radical prostatectomy, to produce a sustained biochemical response during the first 6 months of treatment.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Novartis Investigative Site, Aachen, , Germany
Novarts Investigative Site, Berlin, , Germany
Novartis Investigative Site, Bonn, , Germany
Novartis Investigative Site, Borken, , Germany
Novartis Investigative Site, Darmstadt, , Germany
Novartis Investigative Site, Fürth, , Germany
Novartis Investigative Site, Gardelegen, , Germany
Novarts Investigative Site, Hamburg, , Germany
Novartis Investigative Site, Köln, , Germany
Novartis Investigative Site, Marburg, , Germany
Novartis Investigative Site, Ulm, , Germany
Novartis Investigative Site, Wesel, , Germany
Novartis Investigative Site, Wuppertal, , Germany
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
